Repositorio Digital de la UPF
Publicación
Artículo científico (JournalArticle)
Lipidomic signature of stroke recurrence after transient ischemic attack
While TIA patients have transient symptoms, they should not be underestimated, as they could have an underlying pathology that may lead to a subsequent stroke: stroke recurrence (SR). Previously, it has been described the involvement of lipids in different vascular diseases. The aim of the current study was to perform a lipidomic analysis to identify differences in the lipidomic profile between patients with SR and patients without. Untargeted lipidomic analysis was performed in plasma samples of 460 consecutive TIA patients recruited < 24 h after the onset of symptoms. 37 (8%) patients suffered SR at 90 days. Lipidomic profiling disclosed 7 lipid species differentially expressed between groups: 5 triacylglycerides (TG), 1 diacylglyceride (DG), and 1 alkenyl-PE (plasmalogen) [specifically, TG(56:1), TG(63:0), TG(58:2), TG(50:5), TG(53:7, DG(38:5)) and PE(P-18:0/18:2)]. 6 of these 7 lipid species belonged to the glycerolipid family and a plasmalogen, pointing to bioenergetics pathways, as well as oxidative stress response. In this context, it was proposed the PE(P-18:0/18:2) as potential biomarker of SR condition.The observed changes in lipid patterns suggest pathophysiological mechanisms associated with lipid droplets metabolism and antioxidant protection that is translated to plasma level as consequence of a more intensive or high-risk ischemic condition related to SR., This study was supported by the Government of Catalonia-Agència de Gestió d'Ajuts Universitaris i de Recerca (FP: 2017SGR1628 and 2021SGR01479; RP: 2021SGR00990); Instituto de Salud Carlos III and co-funded by European Union (ERDF/ESF, "Investing in your future" and "A way to build Europe") (FP: PI17-01725, PI14/01574; M.P-O: PI 17-00134, 20-0155); the Spanish Ministry of Science, Innovation and Universities (RP: RTI2018-099200-B-I00 and PID2022-143140OB-I00); the Department of Health (RP: SLT002/16/00250); and the INVICTUS plus Research Network (Carlos III Health Institute) (FP, CT and GA: RD16-0019-0017; TS: RD16-0019-0012; AO and JR: RD16-0019-0012; AC: RD16-0019-0006. M.J. is a professor under the Serra Hunter program (Generalitat de Catalunya).